The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England
Open accessAbstract
BACKGROUND: Antidepressants, opioids for non-cancer pain, gabapentinoids (gabapentin and pregabalin), benzodiazepines, and Z-drugs (zopiclone, zaleplon, and zolpidem) are commonly prescribed medicine classes associated with a risk of dependence or withdrawal. We aimed to review the evidence for these harms and estimate the prevalence of dispensed prescriptions, their geographical distribution, and duration of continuous receipt using all patient-linked prescription data in England. METHODS: This was a mixed-methods public health review, comprising a rapid evidence assessment of articles (Jan 1, 2008, to Oct 3, 2018; with searches of MEDLINE, Embase, and PsycINFO, and the Cochrane and King's Fund libraries), an open call-for-evidence on patient experience and service evaluations, and a retrospective, patient-linked analysis of the National Health Service (NHS) Business Services Authority prescription database (April 1, 2015, to March 30, 2018) for all adults aged 18 years and over. Indirectly (sex and age) standardised rates (ISRs) were computed for all 195 NHS Clinical Commissioning Groups in England, containing 7821 general practices for the geographical analysis. We used publicly available mid-year (June 30) data on the resident adult population and investigated deprivation using the English Indices of Multiple Deprivation (IMD) quintiles (quintile 1 least deprived, quintile 5 most deprived), with each patient assigned to the IMD quintile score of their general practitioner's practice for each year. Statistical modelling (adjusted incident rate ratios [IRRs]) of the number of patients who had a prescription dispensed for each medicine class, and the number of patients in receipt of a prescription for at least 12 months, was done by sex, age group, and IMD quintile. FINDINGS: 77 articles on the five medicine classes were identified from the literature search and call-for-evidence. 17 randomised placebo-controlled trials (6729 participants) reported antidepressant-associated withdrawal symptoms. Almost all studies were rated of very low, low, or moderate quality. The focus of qualitative and other reports was on patients' experiences of long-term antidepressant use, and typically sudden onset, severe, and protracted withdrawal symptoms when medication was stopped. Between April 1, 2017, and March 31, 2018, 11·53 million individuals (26·3% of residents in England) had a prescription dispensed for at least one medicine class: antidepressants (7·26 million [16·6%]), opioids (5·61 million [12·8%]), gabapentinoids (1·46 million [3·3%]), benzodiazepines (1·35 million [3·1%]), and Z-drugs (0·99 million [2·3%]). For three of these medicine classes, more people had a prescription dispensed in areas of higher deprivation, with adjusted IRRs (referenced to quintile 1) ranging from 1·10 to 1·24 for antidepressants, 1·20 to 1·85 for opioids, and 1·21 to 1·85 for gabapentinoids across quintiles, and higher ISRs generally concentrated in the north and east of England. In contrast, the highest ISRs for benzodiazepines and Z-drugs were generally in the southwest, southeast, and east of England, with low ISRs in the north. Z-drugs were associated with increased deprivation, but only at the highest quintile (adjusted IRR 1·11 [95% CI 1·01-1·22]). For benzodiazepines, prescribing was reduced for people in quintiles 4 (0·90 [0·85-0·96]) and 5 (0·89 [0·82-0·97]). In March, 2018, for each of medicine class, about 50% of patients who had a prescription dispensed had done so continuously for at least 12 months, with the highest ISRs in the north and east. Long-term prescribing was associated with a gradient of increased deprivation. INTERPRETATION: In 1 year over a quarter of the adult population in England had a prescription dispensed for antidepressants, opioids (for non-cancer pain), gabapentinoids, benzodiazepines, or Z-drugs. Long-term (>12 months) prescribing is common, despite being either not recommended by clinical guidelines or of doubtful efficacy in many cases. Enhanced national and local monitoring, better guidance for personalised care, and better doctor-patient decision making are needed. FUNDING: Public Health England.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and treatments targeted at insomnia may improve 499 and prevent depression. 500”
From Time for united action on depression: a Lancet–World Psychiatric Association Commission (2022) · cites this paper as [499]
In the citing paper
“In this respect, antidepressants do not differ from other dependence-forming central nervous system (CNS) drugs like benzodiazepines, opioids, gabapentinoids, or psychostimulants.3,19–22”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [3]
In the citing paper
“Following initial reports from this Journal (53) the gabapentinoids pregabalin and gabapentin have been clearly identified as possessing a distinct potential for misuse (54).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,586
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
Sensitivity analysis in observational research: Introducing the E-value
VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Assessing Bias in Studies of Prognostic Factors
Hayden, J. A., van der Windt, D. A., Cartwright, J. L., Côté, P., & Bombardier, C. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-4-201302190-00009 · Cited by 3,287
A classification of chronic pain for ICD-11
Treede, R.-D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R., Cohen, M., Evers, S., Finnerup, N. B., First, M. B., et al. (2015) · Pain · doi:10.1097/j.pain.0000000000000160 · Cited by 2,822
Cited by
Sorted by citations
Time for united action on depression: a Lancet–World Psychiatric Association Commission
Herrman, H., Patel, V., Kieling, C., Berk, M., Buchweitz, C., Cuijpers, P., Furukawa, T. A., Kessler, R. C., Kohrt, B. A., Maj, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02141-3 · Cited by 1,104
Mitigating and learning from the impact of COVID‐19 infection on addictive disorders
Marsden, J., Darke, S., Hall, W., Hickman, M., Holmes, J., Humphreys, K., Neale, J., Tucker, J., & West, R. (2020) · Addiction · doi:10.1111/add.15080 · Cited by 231
Self-citationFerreira, G. E., Lin, C. C., Zadro, J. R., O’Keeffe, M., Shaheed, C. A., McLachlan, A. J., & Maher, C. G. (2021) · BMJ · doi:10.1136/bmj.m4825 · Cited by 179
Jani, M., Yimer, B. B., Sheppard, T., Lunt, M., & Dixon, W. G. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003270 · Cited by 162
Torrance, N., Veluchamy, A., Zhou, Y., Fletcher, E. H., Moir, E., Hébert, H. L., Donnan, P. T., Watson, J., Colvin, L., & Smith, B. H. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.05.017 · Cited by 90
Hengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
Hengartner, M. P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320921694 · Cited by 72
Is Europe Facing an Emerging Opioid Crisis Comparable to the U.S.?
van Amsterdam, J., Pierce, M., & van den Brink, W. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000789 · Cited by 72
Alenezi, A. A., Yahyouche, A., & Paudyal, V. (2020) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-020-01205-y · Cited by 52
Wood, C., Polley, M., Barton, J. L., & Wicks, C. L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192013612 · Cited by 49
Chiappini, S., Schifano, F., Corkery, J., & Guirguis, A. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959615 · Cited by 45
Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study
Groot, P. C., & van Os, J. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211039327 · Cited by 38
Outcome of antidepressant drug discontinuation with taperingstrips after 1–5 years
Groot, P. C., & van Os, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320954609 · Cited by 35
Chiappini, S., Vickers‐Smith, R., Guirguis, A., Corkery, J., Martinotti, G., & Schifano, F. (2022) · Pharmaceuticals · doi:10.3390/ph15050565 · Cited by 38
Diagnosis and Management of Neuropathic Pain in Spine Diseases
Bielewicz, J., Kamieniak, M., Szymoniuk, M., Litak, J., Czyżewski, W., & Kamieniak, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041380 · Cited by 29
Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT
Duffy, L., Clarke, C. S., Lewis, G., Marston, L., Freemantle, N., Gilbody, S. M., Hunter, R. M., Kendrick, T., Kessler, D. S., King, M., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25690 · Cited by 26
‘Z-trip’? A Comprehensive Overview and a Case-series of Zolpidem Misuse
Orsolini, L., Chiappini, S., Grandinetti, P., Bruschi, A., Testa, R., Provenzano, A., Berardis, D. D., & Volpe, U. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.367 · Cited by 24
Moncrieff, J., Read, J., & Horowitz, M. A. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100765 · Cited by 20
Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs
Schifano, F. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507897 · Cited by 18
Leeuwen, E. V., Anthierens, S., van Driel, M., Sutter, A. D., Beir, R. D., & Christiaens, T. (2022) · Acta Clinica Belgica · doi:10.1080/17843286.2021.2024384 · Cited by 17
Social prescribing for frequent attenders in primary care: An economic analysis
Lynch, M., & Jones, C. R. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.902199 · Cited by 17
Coombes, H., & Cooper, R. J. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0170-4 · Cited by 16
Denee, T., Kerr, C., Ming, T., Wood, R., Tritton, T., Middleton-Dalby, C., Massey, O., & Desai, M. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.026 · Cited by 16
Hypnotic use and the risk of cardiovascular diseases in insomnia patients
Xie, Y., Zhu, S., Wu, S., Liu, C., Shen, J. F., Jin, C., Ma, H., & Xiang, M. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae263 · Cited by 14
Denee, T., Ming, T., Waller, J., Bailey, T., Rajkovic-Hooley, O., Middleton-Dalby, C., Le, H. H., Zhang, Q., McCrone, P., & Taylor, D. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1857580 · Cited by 12
Sedative drug-use in Denmark, 2000 to 2019: a nationwide drug utilization study
Rosenqvist, T. W., Osler, M., Wium‐Andersen, M. K., & Wium‐Andersen, I. K. (2022) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-022-02409-5 · Cited by 12
Gu, X., Chen, T., Su, T., Steinke, D. T., & Chen, L. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14827 · Cited by 11
Offu, O. F., Visram, S., Rathbone, A. P., & Lindsey, L. (2023) · International Journal of Pharmacy Practice · doi:10.1093/ijpp/riad090 · Cited by 11
Averting a UK opioid crisis: getting the public health messages ‘right’
Richards, G. C., Anwar, S., & Quinlan, J. (2022) · Journal of the Royal Society of Medicine · doi:10.1177/01410768221089015 · Cited by 11
Glancy, M., Palmateer, N. E., Yeung, A., Hickman, M., Macleod, J., Bishop, J., Barnsdale, L. R., Trayner, K. M. A., Priyadarshi, S., Wallace, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116028 · Cited by 10
Wisłowska-Stanek, A., Jarkiewicz, M., & Mirowska-Guzel, D. M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00689-z · Cited by 11
Yu, D., Appleyard, T., Cottrell, E., & Peat, G. (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa586 · Cited by 10
Progress in GABAA receptor agonists for insomnia disorder
Wang, W., Fu, W., Zhu, H., Ma, J., Zhang, J., & Qi, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1432726 · Cited by 11
Hansen, C. A., Ernst, M. T., Smith, C., & Abrahamsen, B. (2023) · Journal of Pain Research · doi:10.2147/jpr.s388674 · Cited by 9
Trends in risky prescriptions of opioid analgesics from 2011 to 2015 in Northern Germany
Verthein, U., Buth, S., Daubmann, A., Martens, M., & Schulte, B. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936544 · Cited by 10
Usages et bon usage des benzodiazépines anxiolytiques et hypnotiques
Bonnay, M., Soeiro, T., Mégard, R., Micallef, J., Rolland, B., & Chappuy, M. (2021) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2021.08.009 · Cited by 10
Bowers, H. M., Kendrick, T., van Ginneken, N., Glowacka, M., Williams, S. J., Leydon, G., May, C. R., Dowrick, C. F., Moncrieff, J., Johnson, C. F. A., et al. (2021) · Journal of Medical Internet Research · doi:10.2196/25537 · Cited by 8
Misuse of medication in adult substance misuse services: a systematic review protocol
Gittins, R., Missen, L., & Maidment, I. D. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047283 · Cited by 8
Schaffer, A. L., Andrews, C. D., Brown, A. D., Croker, R., Hulme, W. J., Nab, L., Quinlan, J., Speed, V., Wood, C., Wiedemann, M., et al. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00100-2 · Cited by 7
Gould, S. L., Winter, M. J., Trznadel, M., Lange, A., Hamilton, C. M., Boreham, R., Hetheridge, M. J., Young, A. M. J., Norton, W., & Tyler, C. R. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.3c08126 · Cited by 7
Severe chronic abuse of zolpidem for over 10 years: a case report and review of similar cases
Moshfeghinia, R., Jazi, K., Kabaranzadghadim, S., Malekpour, M., & Oji, B. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1252397 · Cited by 7
Clarke, C. S., Duffy, L., Lewis, G., Freemantle, N., Gilbody, S. M., Kendrick, T., Kessler, D. S., King, M., Lanham, P., Mangin, D. A., et al. (2021) · Applied Health Economics and Health Policy · doi:10.1007/s40258-021-00693-x · Cited by 7
Cousins, G., Durand, L., O’Kane, A., Tierney, J., Maguire, R., Stokes, S., O’Reilly, D., Arensman, E., Bennett, K., Vázquez, M. O., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069665 · Cited by 6
Lui, L. M. W., Lee, Y. L., Lipsitz, O., Rodrigues, N. B., Gill, H., Ma, J., Wilkialis, L., Tamura, J. K., Siegel, A. N., Chen-Li, D. C. J., et al. (2021) · CNS Spectrums · doi:10.1017/s1092852921000055 · Cited by 7
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Sun, Y., Zhao, H., Chang, M., Yue, T., Yuan, Y., & Shi, Y. (2024) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.13825 · Cited by 5
Campagnari, S., Zamboni, L., Fusina, F., Casari, R., & Lugoboni, F. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1033061 · Cited by 5
Durand, L., Keenan, E., O’Reilly, D., Bennett, K., O’Hara, A., & Cousins, G. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05195-9 · Cited by 5
Durand, L., Arensman, E., Corcoran, P. E., Daly, C., Bennett, K., Lyons, S., Keenan, E., & Cousins, G. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112669 · Cited by 6
Adjunctive benzodiazepines in depression: a clinical dilemma with no recent answers from research
de Cates, A. N., & Giorgi, R. D. (2020) · BJPsych Advances · doi:10.1192/bja.2020.17 · Cited by 5
Jeffries, M., Abuzour, A. S., Ashcroft, D. M., Avery, A. J., Langridge, M., Francis, G., O'Brien, A., Millington, T., & Keers, R. N. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-086309 · Cited by 7
Zhang, Z., Yang, Q., Chen, M., Yang, W., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1385651 · Cited by 4
O'Brien, D., Healy, A. M., Harkin, A., & Cadogan, C. A. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70082 · Cited by 5
Determinants of long‐term opioid prescribing in an urban population: A cross‐sectional study
Naughton, M., Redmond, P., Durbaba, S., Ashworth, M. J., & Molokhia, M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15231 · Cited by 4
Gittins, R., Missen, L., & Maidment, I. (2022) · Substance Abuse Research and Treatment · doi:10.1177/11782218221111833 · Cited by 4
Xu, X., Wang, X., Zhong, N., Xu, J., Li, C., Wang, G., Wang, W., Ye, Y., Chen, Y., Liu, T., et al. (2022) · BJPsych Open · doi:10.1192/bjo.2022.589 · Cited by 4
Gittins, R., Vaziri, R., & Maidment, I. D. (2022) · Substance Abuse Research and Treatment · doi:10.1177/11782218221135875 · Cited by 4
Begley, E., Poole, H. M., Sumnall, H. R., Frank, B., & Montgomery, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280958 · Cited by 4
Bischof, G., Otto, C., Bischof, A., & Rumpf, H. (2020) · Suchttherapie · doi:10.1055/a-1128-5050 · Cited by 4
An insight into zolpidem abuse and dependence
Świąder, K., Szymańska, E., Ostaszewska, S., Augustynowicz, K., Chrzanowski, J., Łoginoff, J., Morawski, P., Popińska, Z., & Pactwa, F. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.13.03.033 · Cited by 3
Vittengl, J. R., Jarrett, R. B., Ro, E., & Clark, L. A. (2023) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-230016 · Cited by 3
Bansal, N., Campbell, S., Lin, C.-Y., Ashcroft, D. M., & Chen, L. (2024) · BMC Medicine · doi:10.1186/s12916-023-03213-x · Cited by 3
Silczuk, A., & Heitzman, J. (2020) · Psychiatria Polska · doi:10.12740/pp/115555 · Cited by 3
Missbrauch und Abhängigkeit von Benzodiazepinen und Z-Drugs
Soyka, M. (2021) · Nervenheilkunde · doi:10.1055/a-1523-5718 · Cited by 3
Dependência química induzida pelo uso de benzodiazepínicos na senescencia
da Silva, A. A., & de Souza, G. O. (2021) · Research Society and Development · doi:10.33448/rsd-v10i14.22321 · Cited by 3
Private prescribing of controlled opioids in England, 2014–2021: a retrospective observational study
Martus, I., MacKenna, B., Rial, W., HAYHURST, J. W., & Richards, G. C. (2023) · British Journal of General Practice · doi:10.3399/bjgp.2023.0146 · Cited by 3
Editorial: Prescribing psychotropics: Misuse, abuse, dependence, withdrawal and addiction, Volume II
Chiappini, S., Schifano, F., & Martinotti, G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1053896 · Cited by 3
Synaptic correlates of benzodiazepine tolerance
Piot, A., & Jovanovic, J. N. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03512-8 · Cited by 4
Soyka, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00033-5 · Cited by 2
Identity Construction and Stigma in Recovery
Murphy, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-98286-7_4 · Cited by 2
Poole, H. M., Frank, B., Begley, E., Woods, A., Silva, A. R., Merriman, M., McCulough, R., & Montgomery, C. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-065646 · Cited by 2
Aljohani, D. M., Almalki, N. J., Adam, R., & Forget, P. (2023) · European Journal of Anaesthesiology Intensive Care · doi:10.1097/ea9.0000000000000024 · Cited by 2
Chiappini, S., Guirguis, A., Corkery, J., & Schifano, F. (2020) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2020.20208538 · Cited by 40
Gittins, R., Vaziri, R., & Maidment, I. D. (2023) · Drug Science Policy and Law · doi:10.1177/20503245231215407 · Cited by 1
Zhang, M., Li, Q., Li, S., Sun, B., Wu, Z., Liu, J., Geng, X., & Chen, F. (2025) · Toxics · doi:10.3390/toxics13070586 · Cited by 1
Saskin, P., McCall, W. V., Neubauer, D. N., Crucitti, A., Perry, B., Luyet, P.-P., Jaziri, R., & Vaillant, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1735180 · Cited by 1
Association between regular hypnotic use and age-related macular degeneration
Chen, J., Tu, S., Zhu, Y., Li, Z., Chen, X., Shen, X., Deng, S., & Zhuo, Y. (2026) · Advances in Ophthalmology Practice and Research · doi:10.1016/j.aopr.2026.03.001 · Cited by 1
Wang, Y., Fahmi, A., Woodall, A., Ashcroft, D. M., Sperrin, M., & van Staa, T. P. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10588 · Cited by 1
Khan, Z., Doherty, A. S., McCarthy, C., Dalton, K., Jungo, K. T., Reeve, E., & Moriarty, F. (2026) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2026.100828 · Cited by 1
Prescribing in primary care: art versus algorithm
SHOPTAW, S. J., Nguyen, D. B., & Giang, L. M. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30373-6 · Cited by 1
Managing Older Adults' Chronic Pain
Arnstein, P. M., Shade, M. Y., Herr, K., Young, H. M., & Fishman, S. M. (2023) · Home Healthcare Now · doi:10.1097/nhh.0000000000001203 · Cited by 1
González, D. F. G., Teixeira-da-Silva, P., Sánchez, J. J. S., Serrano, J. Á. S., Calvo, M. V. M., & Martín‐Suárez, A. (2024) · Pharmaceuticals · doi:10.3390/ph17040460 · Cited by 1
Roberts, E., Copeland, C. S., Darke, S. G., & Farrell, M. (2024) · Drug and Alcohol Review · doi:10.1111/dar.13950 · Cited by 1
Validity and reliability of the Japanese version of the Substance Use Stigma Mechanism Scale
Takano, A., Hiraiwa, C., Oikawa, E., Tomikawa, A., & Nozawa, K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310514 · Cited by 1
Delloye, E., Wauters, V., Masabarakiza, J. B., & Dupriez, F. (2021) · Acta Clinica Belgica · doi:10.1080/17843286.2021.1899696 · Cited by 1
Stupak, R. (2021) · Praktyka Teoretyczna · doi:10.14746/prt.2021.2.6 · Cited by 1
Opioid prescribing and medical education: can primary care fill in the gaps?
Alfuhaid, R. (2022) · British Journal of General Practice · doi:10.3399/bjgp22x721097 · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Gründer, G. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21199-7.00004-0 · Cited by 1
Dependence on prescription medication
Lucas, J. (2022) · InnovAiT Education and inspiration for general practice · doi:10.1177/17557380211070618
Markozova, L. (2022) · Ukrains kyi Visnyk Psykhonevrolohii · doi:10.36927/2079-0325-v30-is2-2022-12
Gittins, R., Teck, J. T. W., & Madill, A. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221132548
Managing Older Adults' Chronic Pain: Higher-Risk Interventions
Arnstein, P. M., Shade, M. Y., Herr, K., Young, H. M., & Fishman, S. M. (2023) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000925528.83750.03
Piton, V. A., André, G. S. S., Oliveira, A. F. D., Jacomini, T. G., Castro, R. C. D., Faria, T. V., & Iembo, T. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n1-086
Durand, L., Keenan, E., O’Reilly, D., Bennett, K., O’Hara, A., & Cousins, G. (2023) · Figshare · doi:10.6084/m9.figshare.24264630
Wilson, L. E., Knaggs, R., Avery, A. J., Thornley, T., Moss, J., Baamer, R. M., & Boyd, M. (2025) · PAIN Reports · doi:10.1097/pr9.0000000000001246
Insomnia Alleviated with Accelerated Resolution Therapy: Two Case Studies
Tofthagen, C., Foster, R., Bennett, C., & Donovan, K. A. (2025) · Journal of Palliative Medicine · doi:10.1089/jpm.2024.0218
Offu, O. F., Okeowo, D. A., Visram, S., Rathbone, A. P., & Lindsey, L. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-099801
Kauye, F., Wijesundara, A., & Mwandumba, D. (2025) · Clinical Practice and Epidemiology in Mental Health · doi:10.2174/0117450179375369250623061653
Chen, T., Trafford, A. M., Carr, M., Bansal, N., Kontopantelis, E., Avery, A. J., Chen, L., & Ashcroft, D. M. (2025) · BMJ Quality & Safety · doi:10.1136/bmjqs-2025-018794
Metadata
- Authors
- Marsden, J., White, M., Annand, F., Burkinshaw, P., Carville, S., Eastwood, B., Kelleher, M., Knight, J., O'Connor, R., Tran, A., Willey, P., Greaves, F., & Taylor, S.
- Affiliations
- King's College London (GB)
- Public Health England (GB)
- Royal College of Physicians (GB)
- South London and Maudsley NHS Foundation Trust (GB)
- Corresponding author
- Marsden, John
- ORCID
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 6
- Issue
- 11
- Pages
- 935-950
- ISSN
- 2215-0366 (ISSN-L)
- PMC
- PMC7029276
- OpenAlex
- W2978303387
- Cited by
- 106
- References
- 40
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 15 · 2023: 15 · 2022: 18 · 2021: 18 · 2020: 17 · 2019: 2
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet Psychiatry (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, cc-by-nc-nd)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- Merck
- National Institute for Health and Care Research
- Imperial College London
- Public Health England
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- drug addiction, drug withdrawal, antidepressants, opioid analgesics, gabapentinoids, benzodiazepines, Z-drugs, prescription prevalence, socioeconomic deprivation, antidepressant withdrawal symptoms, benzodiazepine withdrawal, patient experience, England, clinical commissioning groups
- MeSH terms
- Pregabalin, Gabapentin, Zolpidem, Acetamides, Adolescent, Adult, Aged, Analgesics, Analgesics, Opioid, Antidepressive Agents, Benzodiazepines, England, Female, Humans, Hypnotics and Sedatives, Male, Middle Aged, Piperazines, Public Health, Pyrimidines, Substance Withdrawal Syndrome, Databases, Factual, Substance-Related Disorders, Azabicyclo Compounds, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
